Cipla Share Price in Focus; USFDA Inspects InvaGen Facility, Receives One Form 483 Observation

Cipla Limited has informed exchanges that the United States Food and Drug Administration (USFDA) conducted a routine inspection at the manufacturing facility of its wholly owned subsidiary, InvaGen Pharmaceuticals Inc., in Central Islip, Long Island, New York. 

The inspection concluded with the issuance of one inspectional observation in Form 483, which the company said it will address in coordination with the USFDA.  

USFDA Conducts Routine Inspection 

The USFDA carried out a current Good Manufacturing Practices (cGMP) inspection at InvaGen's manufacturing facility from July 13 to July 17, 2026 (EDT). 

According to the company, the inspection was part of the regulator's routine manufacturing compliance process.  

Facility Receives One Form 483 Observation 

At the conclusion of the inspection, the USFDA issued one inspectional observation in Form 483. 

A Form 483 is issued when investigators identify conditions that may require corrective action during an inspection. It does not constitute a final regulatory action or indicate non-compliance by itself.  

Cipla to Respond within Stipulated Timeline 

Cipla said it will work closely with the USFDA and is committed to addressing the observation comprehensively within the stipulated timeframe. 

The company did not disclose any impact on manufacturing operations arising from the inspection.  

Read More: Kotak Mahindra Bank Share Price in Focus After Q1 FY27 Earnings Results: Total Income Up 12.6% YoY! 

Cipla Share Price Performance 

As of 17 July 2026, Cipla share price was closed at ₹1,418.70 per share, reflecting a decline of 0.76% from the previous trading session. 

Conclusion 

The USFDA's routine inspection of InvaGen's manufacturing facility concluded with a single Form 483 observation. Cipla has stated that it will work with the regulator to address the observation within the prescribed timeline.  

Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.